Fingerprint
Dive into the research topics of 'Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically